{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:27:48Z","timestamp":1778041668653,"version":"3.51.4"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ymgme.2022.03.011","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T20:22:45Z","timestamp":1648498965000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias"],"prefix":"10.1016","volume":"136","author":[{"given":"Teodoro","family":"Jerves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nenad","family":"Blau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos R.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2022.03.011_bb0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ymgme.2019.03.007","article-title":"Clinical and biochemical footprints of inherited metabolic diseases. I. Movement disorders","volume":"127","author":"Ferreira","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ymgme.2019.04.002","article-title":"Clinical and biochemical footprints of inherited metabolic diseases. II. Metabolic liver diseases","volume":"127","author":"Ferreira","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2020.02.007","article-title":"Clinical and biochemical footprints of inherited metabolic diseases. III. Psychiatric presentations","volume":"130","author":"Horvath","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2020.12.290","article-title":"Clinical and biochemical footprints of inherited metabolic diseases. IV. Metabolic cardiovascular disease","volume":"132","author":"Ferreira","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0025","article-title":"Clinical and biochemical footprints of inherited metabolic disease. V. Cerebral palsy phenotypes","author":"Horvath","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ymgme.2021.07.005","article-title":"Clinical and biochemical footprints of inherited metabolic diseases. VI. Metabolic dermatoses","volume":"134","author":"Ferreira","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.02.002","article-title":"Clinical and biochemical footprints of inherited metabolic disorders. VII. Ocular phenotypes","author":"Garanto","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/gim.2017.108","article-title":"Knowledge base and mini-expert platform for the diagnosis of inborn errors of metabolism","volume":"20","author":"Lee","year":"2018","journal-title":"Genet Med."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0045","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41436-018-0022-8","article-title":"A proposed nosology of inborn errors of metabolism","volume":"21","author":"Ferreira","year":"2019","journal-title":"Genet Med."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0050","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/jimd.12348","article-title":"ICIMD advisory group, an international classification of inherited metabolic disorders (ICIMD)","volume":"44","author":"Ferreira","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0055","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nrc3949","article-title":"Metabolic dysregulation in monogenic disorders and cancer - finding method in madness","volume":"15","author":"Erez","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0060","first-page":"23","article-title":"A review article on the basic concepts of drug delivery systems as targeting agents","volume":"10","author":"Elsewedy","year":"2021","journal-title":"Int. J. Pharma Med. Biol. Sci"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0065","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and trends\u2013an update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0075","series-title":"Tumors and Tumor-Like Lesions of the Hepatobiliary Tract: General and Surgical Patholo","first-page":"2931","article-title":"Etiology and pathogenesis of hepatocellular carcinoma: inflammatory and toxic causes","author":"Zimmermann","year":"2017"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0080","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.3748\/wjg.v24.i35.3980","article-title":"Pediatric hepatocellular carcinoma","volume":"24","author":"Khanna","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0085","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1158\/1055-9965.EPI-18-1169","article-title":"Current prevalence of major cancer risk factors and screening test use in the United States: disparities by education and race\/ethnicity","volume":"28","author":"Goding Sauer","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0090","first-page":"764","article-title":"Hereditary leiomyomatosis and renal cell cancer: clinical, molecular, and screening features in a cohort of 185 affected individuals","volume":"3","author":"Forde","year":"2020","journal-title":"EurUrol. Oncol."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0095","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1210\/jc.2014-2151","article-title":"Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas\/paragangliomas due to succinate dehydrogenase deficiency","volume":"99","author":"Richter","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0100","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/35077207","article-title":"Cancer genetics","volume":"411","author":"Ponder","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0105","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ajhg.2011.03.005","article-title":"Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism","volume":"88","author":"Erez","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/biom10040568","article-title":"Methionine dependence of cancer","volume":"10","author":"Kaiser","year":"2020","journal-title":"Biomolecules."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0115","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41568-018-0054-z","article-title":"Rewiring urea cycle metabolism in cancer to support anabolism","volume":"18","author":"Keshet","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0120","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s12276-020-00504-8","article-title":"Glutamine reliance in cell metabolism","volume":"52","author":"Yoo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0125","doi-asserted-by":"crossref","first-page":"31664","DOI":"10.18632\/oncotarget.25839","article-title":"Inborn-like errors of metabolism are determinants of breast cancer risk, clinical response and survival: a study of human biochemical individuality","volume":"9","author":"da Silva","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0130","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3390\/cells9102308","article-title":"Cancer metabolism: phenotype, signaling and therapeutic targets","volume":"9","author":"Park","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0135","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ajpath.2013.07.035","article-title":"Is cancer a metabolic disease?","volume":"184","author":"Coller","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0140","first-page":"4213","article-title":"Crucial role of the pentose phosphate pathway in malignant tumors","volume":"17","author":"Jin","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0145","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cmet.2021.04.003","article-title":"Evolving concepts in NAD+ metabolism","volume":"33","author":"Chini","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s42255-020-00329-9","article-title":"The ins and outs of serine and glycine metabolism in cancer","volume":"3","author":"Geeraerts","year":"2021","journal-title":"Nat Metab."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau9529","article-title":"p53 is regulated by aerobic glycolysis in cancer cells by the CtBP family of NADH-dependent transcriptional regulators","volume":"13","author":"Birts","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0160","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.semcdb.2019.05.031","article-title":"The multifaceted contribution of \u03b1-ketoglutarate to tumor progression: an opportunity to exploit?","volume":"98","author":"Abla","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.07.019","article-title":"Urea cycle dysregulation generates clinically relevant genomic and biochemical signatures","volume":"174","author":"Lee","year":"2018","journal-title":"Cell."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0170","article-title":"A metabolic link between the urea cycle and cancer cell proliferation","volume":"3","author":"Nagamani","year":"2016","journal-title":"Mol.Cell. Oncol."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0175","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ymgme.2018.10.001","article-title":"Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword","volume":"128","author":"Peoc\u2019h","year":"2019","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0180","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/hep.31460","article-title":"Hepatocellular carcinoma in acute hepatic porphyrias: results from the longitudinal study of the U.S. Porphyrias consortium","volume":"73","author":"Saberi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0185","article-title":"Development of hepatocellular carcinoma in patients with glycogen storage disease: a single center retrospective study","volume":"35","author":"Jang","year":"2019","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0190","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2006.09.022","article-title":"Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?","volume":"46","author":"Demo","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0195","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1373\/clinchem.2016.267666","article-title":"Oncometabolites: a new paradigm for oncology, metabolism, and the clinical laboratory","volume":"63","author":"Collins","year":"2017","journal-title":"Clin Chem."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101416","article-title":"An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma","volume":"34","author":"Buffet","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0205","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jnci\/djab158","article-title":"Germline SUCLG2 variants in patients with pheochromocytoma and paraganglioma","volume":"114","author":"Hadrava Vanova","year":"2022","journal-title":"JNCI: J. National Cancer Instit."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0210","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.2932","article-title":"Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status","volume":"225","author":"Bardella","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.mito.2016.05.002","article-title":"Prevalence of neoplasms in definite and probable mitochondrial disorders","volume":"29","author":"Finsterer","year":"2016","journal-title":"Mitochondrion"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229834","article-title":"MPV17 does not control cancer cell proliferation","volume":"15","author":"Canonne","year":"2020","journal-title":"PLoS One."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0225","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/archneur.63.8.1129","article-title":"Hepatocerebral mitochondrial DNA depletion syndrome caused by deoxyguanosine kinase (DGUOK) mutations","volume":"63","author":"Freisinger","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0230","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/jimd.12143","article-title":"Liver neoplasms in methylmalonic aciduria: an emerging complication","volume":"42","author":"Forny","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0235","first-page":"3","article-title":"Molecular and clinical characterization of citrin deficiency in a cohort of chinese patients in Hong Kong","volume":"17","author":"Chong","year":"2018","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0240","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10545-017-0022-x","article-title":"Expanding the phenotype in argininosuccinic aciduria: need for new therapies","volume":"40","author":"Baruteau","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0245","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10545-017-0088-5","article-title":"Liver involvement in urea cycle disorders: a review of the literature","volume":"40","author":"Bigot","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0250","doi-asserted-by":"crossref","DOI":"10.1177\/2326409816679429","article-title":"Mechanisms by which metabolic reprogramming in GSD1 liver generates a favorable tumorigenic environment","volume":"4","author":"Gjorgjieva","year":"2016","journal-title":"J. Inborn Errors Metabol.Screen."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2019.11.061","article-title":"Activation of tumor-promoting pathways implicated in hepatocellular adenoma\/carcinoma, a long-term complication of glycogen storage disease type ia","volume":"522","author":"Cho","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0260","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1615\/CritRevOncog.2013006145","article-title":"Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism","volume":"18","author":"Mistry","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0265","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3390\/ijms20040843","article-title":"Defective sphingolipids metabolism and tumor associated macrophages as the possible links between gaucher disease and blood cancer development","volume":"20","author":"W\u0105tek","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0270","first-page":"185","article-title":"Signs and symptoms of childhood cancer: a guide for early recognition","volume":"88","author":"Fragkandrea","year":"2013","journal-title":"AFP."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0275","doi-asserted-by":"crossref","first-page":"14771","DOI":"10.3390\/ijms140714771","article-title":"Clinical advances in molecular biomarkers for cancer diagnosis and therapy","volume":"14","author":"Sethi","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0280","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.2147\/OTT.S99807","article-title":"Next-generation sequencing: advances and applications in cancer diagnosis","volume":"9","author":"Serrat\u00ec","year":"2016","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0285","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1210\/er.2018-00258","article-title":"Claahsen-van der grinten, testicular adrenal rest tumors: current insights on prevalence, characteristics, origin, and treatment","volume":"40","author":"Engels","year":"2019","journal-title":"Endocrine Rev."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0290","first-page":"141","article-title":"Update in global trends and aetiology of hepatocellular carcinoma","volume":"22","author":"Rawla","year":"2018","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0295","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.29971","article-title":"Population attributable fractions of risk factors for hepatocellular carcinoma in the United States","volume":"122","author":"Makarova-Rusher","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0300","first-page":"290","article-title":"Liver tumors in children with metabolic disorders","volume":"4","author":"Schady","year":"2015","journal-title":"Transl Pediatr."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0305","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/17474124.2021.1946393","article-title":"Metabolic disorders and the risk of cholangiocarcinoma","volume":"15","author":"Ghidini","year":"2021","journal-title":"Exp. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0310","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1542\/peds.2014-1913","article-title":"Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP","volume":"135","author":"van Ginkel","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0315","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1056\/NEJMra1608634","article-title":"Porphyria","volume":"377","author":"Bissell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0320","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-019-1051-3","article-title":"Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study","volume":"14","author":"Baravelli","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0325","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27392","article-title":"Acquired ornithine transcarbamylase deficiency in pediatric and adolescent patients with fibrolamellar hepatocellular carcinoma","volume":"65","author":"Bartlett","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0330","first-page":"47","article-title":"Fibrolamellar hepatocellular carcinoma mimicking ornithine transcarbamylase deficiency","volume":"Volume 16","author":"Sulaiman","year":"2014"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0335","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1634\/theoncologist.2015-0267","article-title":"Hyperammonemic encephalopathy associated with fibrolamellar hepatocellular carcinoma: case report, literature review, and proposed treatment algorithm","volume":"21","author":"Chapuy","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0340","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4143\/crt.2020.575","article-title":"Hyperammonemic encephalopathy mimicking ornithine transcarbamylase deficiency in fibrolamellar hepatocellular carcinoma: successful treatment with continuous venovenous hemofiltration and ammonia scavengers","volume":"53","author":"Lee","year":"2021","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0345","doi-asserted-by":"crossref","first-page":"E5916","DOI":"10.1073\/pnas.1424894112","article-title":"Transcriptomic characterization of fibrolamellar hepatocellular carcinoma","volume":"112","author":"Simon","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0350","first-page":"11","article-title":"Hepatic encephalopathy associated with cancer or anticancer therapy","volume":"6","author":"Willson","year":"2013","journal-title":"GastrointestCancer Res."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0355","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1001\/jama.304.14.1628","article-title":"Cancer: the basics","volume":"304","author":"Torpy","year":"2010","journal-title":"JAMA."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0360","first-page":"23","article-title":"Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I","volume":"Volume 18","author":"Beegle","year":"2015"},{"key":"10.1016\/j.ymgme.2022.03.011_bb0365","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1089\/hum.2019.151","article-title":"Current status on clinical development of adeno-associated virus-mediated liver-directed gene therapy for inborn errors of metabolism","volume":"30","author":"Ginocchio","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0370","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ymgme.2011.10.016","article-title":"Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency","volume":"105","author":"Wilson","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0375","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0380","article-title":"Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia","volume":"10","author":"de Beaumais","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0385","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0390","first-page":"43","article-title":"Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)","volume":"10","author":"Das","year":"2017","journal-title":"ApplClin. Genet."},{"key":"10.1016\/j.ymgme.2022.03.011_bb0395","series-title":"Hepatocellular Carcinoma","author":"El-Serag","year":"2011"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222002815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222002815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:52:43Z","timestamp":1761090763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719222002815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1096719222002815"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.03.011","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}